Navigation Links
OHSU Knight Cancer Institute to study new radiation technology for head, neck cancer
Date:4/28/2009

PORTLAND, Ore. The Oregon Health & Science University Knight Cancer Institute will evaluate whether the state-of-the-art image-guidance system called Calypso (Calypso Medical, Seattle, Wash.) is as effective in delivering highly precise radiation therapy to head and neck cancer patients as it has been in those with prostate cancer.

"We have been extremely happy with the system's performance for prostate cancer, and it is our hope to apply this system to multiple new body sites in the future. This study represents a real first step in that direction," said Patrick Gagnon, M.D., principal investigator and co-chief resident in the Department of Radiation Medicine, OHSU Knight Cancer Institute, OHSU School of Medicine.

The Calypso system relies on three electromagnetic transponders, or beacons, about the size of a grain of rice that are implanted in the prostate prior to beginning treatments. These transponders utilize electromagnetic fields that can be detected with sub-millimeter precision for accurate daily targeting of the prostate gland. Continuous monitoring of the patient and prostate motion is also possible, which allows for greater accuracy in delivering radiation therapy and limits exposure to surrounding healthy tissue.

In this new Phase II clinical trial, the beacons will be implanted into a customized mouth guard fitted to the participant's upper teeth/jaw. With the mouth guard in place, the research team will test whether daily patient positioning can be improved using this system. They will be able to monitor the participant's movement in real time throughout the seven-week course of treatment. This has proved difficult in the past without exposing the patient to additional radiation.

"The Calypso system is unique in allowing the treatment team to continuously monitor the patient's position as the procedure is under way. Unlike other technologies, it doesn't require additional radiation exposure to provide the movement and localization feedback we need," explained Gagnon.

This new research is funded in part through a grant from The American Society of Clinical Oncology (ASCO) Cancer Foundation, which recently awarded Gagnon its highly coveted 2009 Young Investigator Award for his groundbreaking work in this area.

"Only about 30 of these awards are given nationally each year, and only two to four go to radiation oncology junior faculty/trainees. We are proud of Dr. Gagnon's achievement and are excited to be able to offer this leading-edge technology to another group of cancer patients," said Charles Thomas, M.D., chairman of the Department of Radiation Medicine, OHSU Knight Cancer Institute, OHSU School of Medicine.

Gagnon will partner with Thomas and John Holland, M.D., associate professor, Department of Radiation Medicine, OHSU Knight Cancer Institute, OHSU School of Medicine, in conducting this research.

This work is supported by The ASCO Cancer Foundation Award. Any opinions, findings, conclusions expressed in this material are those of the author(s) and do not necessarily reflect those of the American Society of Clinical Oncology or The ASCO Cancer Foundation.


'/>"/>

Contact: Tamara Hargens-Bradley
hargenst@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Intrepid USA Healthcare Services Appoints Kathy McKnight as Chief Operations Officer
2. Knights of Columbus to Distribute Wheelchairs to Veterans in Need
3. Knights to Distribute $1 Million Worth of Wheelchairs for Veterans
4. Knights Distribute $1 Million Worth of Wheelchairs to Veterans
5. Southern Research Institute Names Blaine Knight Vice President of Drug Discovery
6. Jane M. Knight Recognized By Strathmores Whos Who Worldwide Publication
7. Perr&Knight Announces Discounted Fee Schedule for Access to Its Online Database of Commercial Lines Competitor Filings
8. UF McKnight Brain Institute director honored by Italian scientists
9. Holland & Knight Welcomes MARC Associates - Experts in Health Care and Intergovernmental Policy - to the Firms Public Policy & Regulation Practice
10. Knights of Columbus Ultrasound Program Assists Pregnant Women
11. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... PureLife Dental is pleased to announce that California ... members. As part of the amalgam separator endorsement, all CDA members may purchase an ... off the retail value. This partnership between PureLife and CDA is especially timely as ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... Ulster University, ... June, 2017 from 9 am to 3 pm to present to graduate students exciting ... is an original curriculum project led by The Health Improvement Service of the ...
(Date:6/23/2017)... ... June 23, 2017 , ... All-Star Insurance, a family managed agency ... throughout eastern Texas, is announcing the launch of a new charity drive to benefit ... in the United States reveal that an estimated 252, 710 new cases of invasive ...
(Date:6/22/2017)... , ... June 22, 2017 , ... Branches, Inc. has ... than $245,000 in grant funding to support its programs focused on providing opportunity to ... was awarded a grant by the Foundation of $15,000 to support its , Climb ...
(Date:6/22/2017)... ... ... Groove Ring is excited to announce they've partnered with Olympic runner Jared ... all-purpose rings. Whether you’re an athlete, adventurer, professional, or love to venture the great ... the rock face to the auto shop, Groove Ring is the world's first breathable ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... 14, 2017 The Bio Supply Management Alliance ... of Fremont and the Biomedical Manufacturing Network ... in California by providing a ... and fostering workforce development. The primary focus of this ... start-ups, as well as small and mid-sized biomedical companies. ...
(Date:6/13/2017)... June 13, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that the U.S. Food and Drug Administration (FDA) has ... 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning Letter related ... facility is a measure of the progress we have made ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company (NYSE: ... three Phase 3 studies of galcanezumab, an investigational treatment ... late-breaking data on several key secondary endpoints for galcanezumab ... from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be ... scientific meeting in Boston . ...
Breaking Medicine Technology: